EconPapers    
Economics at your fingertips  
 

Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial

Christian Reiterer, Barbara Kabon (), Alexander Taschner, Alexandra Graf, Nikolas Adamowitsch, Katharina Horvath, David Emler, Oliver Zotti, Nicole Hantakova, Beatrix Hochreiter, Melanie Fraunschiel, Theresa Clement and Edith Fleischmann
Additional contact information
Christian Reiterer: Division of General Anaesthesia and Intensive Care Medicine
Barbara Kabon: Division of General Anaesthesia and Intensive Care Medicine
Alexander Taschner: Division of General Anaesthesia and Intensive Care Medicine
Alexandra Graf: Center for Medical Data Science
Nikolas Adamowitsch: Division of General Anaesthesia and Intensive Care Medicine
Katharina Horvath: Division of General Anaesthesia and Intensive Care Medicine
David Emler: Division of General Anaesthesia and Intensive Care Medicine
Oliver Zotti: Division of General Anaesthesia and Intensive Care Medicine
Nicole Hantakova: Division of General Anaesthesia and Intensive Care Medicine
Beatrix Hochreiter: IT Systems and Communications
Melanie Fraunschiel: IT Systems and Communications
Theresa Clement: Division Nursing Science with Focus on Person-centred Care Research
Edith Fleischmann: Division of General Anaesthesia and Intensive Care Medicine

Nature Communications, 2025, vol. 16, issue 1, 1-8

Abstract: Abstract The effect of Levosimendan on postoperative natriuretic peptides in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative N-terminal brain pro natriuretic peptide (NT-proBNP) concentrations. In this prospective, double-blinded, parallel group, placebo-controlled, phase III trial 115 patients were assigned to perioperative single-dose of 12.5 mg of levosimendan and 115 to placebo between October 2020 through November 2023 (clinicaltrials.gov: NCT04329624). The primary outcome was postoperative maximum NT-proBNP concentration within the first 3 postoperative days. 228 patients completed the trial. Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: −64.51 ng.L-1; 95% CI −332.66 to 195.56; p = 0.61). Here, we show that perioperative levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP after noncardiac surgery.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60601-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60601-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60601-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-07-03
Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60601-y